About The Reproductive Times
Introducing a new media entity with limitless opportunities, exclusively dedicated to progress in reproductive sciences and reproductive medicine.
September 3, 2024
The Reproductive Times is a new medium established today by Norbert Gleicher, MD, a lifelong physician, scientist, author, and editor in reproductive medicine, and his team, with the goal of becoming a worldwide source for everything worth knowing in reproductive sciences and reproductive clinical medicine. Meant for a range of audiences in reproduction and reproductive health—interested lay public, basic research scientists, clinicians and embryologists (or “laboratory clinicians,” as we like to call them) —this medium will feature a diverse spread of materials for all interest groups, characterized by honesty, transparency, independence from commercial influences and, yes, at times outspokenness and fearlessness.
Articles may offer basic medical and/or scientific information, investigative stories, relevant worldwide news, an ongoing literature review and, of course, commentaries which at times are purposefully meant to be provocative. We expect to interview interesting guests and to offer their comments on camera as well as transcribed and will do the same with debates on controversial issues.
There is so much happening in the field every day that nobody knows about. Just informing readers about a small fraction of the unknown will make The Reproductive Times a successful endeavor. While you may not agree with everything we publish, we argue that this should be a reason to engage. Dissonance and disagreement drive progress and this is, after all, a common goal for everybody interested in reproduction.
We always look for outside contributors. To get in touch, please write to Hello@ReproductiveTimes.com.
If you are not already subscribed, follow the button below for a free subscription.
~ The Reproductive Times Team
Find our most recent postings below.
Our recent posting features an article by two members of the CHR team that addresses the most important subjects of the CHR’s existence as one of the world’s most unique fertility centers. Nearly 20 years ago, the leadership of the center identified the aging ovary as the likely most important issue in the infertility field in the coming years. As a result, they made the aging ovary the center’s primary focus in both basic research and clinical practice.
This prediction has proven accurate, as older women have recently been the only age group in the U.S. demonstrating growing pregnancy and birth rates. The CHR has benefitted from this trend by developing, through in-house (published) research, several treatments for “older” ovaries. These treatments have radically changed how the CHR — in contrast to most other IVF clinics — approaches the treatment of older ovaries, with considerable and steadily improving success.
The article presented here not only highlights this special expertise but also points out the discrepancy between the median national age of U.S. women undergoing autologous IVF cycles at all reporting IVF clinics and those undergoing autologous cycles at the CHR. For nearly 10 years, the median age in the U.S. has remained around 36 years. In contrast, at the CHR, the median patient age has increased significantly over the last three years, from 42–43 in 2022 to 44 in 2023, and — as we recently learned — to 45 by 2024. This represents a notable increase over just three years, during which the ongoing clinical pregnancy rate for women with at least one embryo for transfer has risen from 8% to 12%, a 33.3% improvement, clearly reflecting the CHR’s increasing expertise in managing older ovaries.
The article, therefore, once again asks: Why do almost all IVF clinics in the U.S. still refuse to treat women above 42-43 years with their own (autologous) eggs? The answer, unfortunately, is not a pretty one.
Additionally, in the general medical literature review, two very “hot” subjects are addressed: artificial intelligence (A.I.) in medicine and anti-aging medicine, both of which are undergoing rapid changes.
About our Founder:
Norbert Gleicher, MD, FACOG, FACS, is an infertility specialist with decades of clinical experience, widely considered one of the original IVF pioneers in the country who – among many other firsts- published the first vaginal egg retrieval under ultrasound control in the world, which changed IVF practice worldwide. He was also for 20 years the founding Editor-in-Chief of the Journal of In Vitro Fertilization and Embryo Transfer, two years later renamed the Journal of Assisted Reproduction and Genetics (JARG). He is also worldwide recognized as a leading reproductive immunologist, and, indeed, was the first Vice-President of the American Society for Reproductive Immunology and the founding Editor-in-Chief of its journal, The American Journal of Reproductive Immunology (AJRM).